Sittard/Leiden, The Netherlands, March 26, 2007 - DSM Biologics, a business unit of DSM Pharmaceutical Products, and Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX), today announced that they have signed a non-exclusive PER.C6® research licensing deal with Taipei, Taiwan-headquartered Development Center for Biotechnology (DCB). DCB will use the PER.C6® human cell line for its in-house production of undisclosed recombinant proteins. This PER.C6® license is Crucell’s second license in Taiwan for recombinant protein production within one year further confirming and complementing the company’s strong focus on Taiwan and Asia in general.
